Abstract
BackgroundMyocardial ischemia is a significant problem in cardiovascular health caused by the obstruction or constriction of coronary arteries, resulting in diminished blood supply to the heart muscle. Translational bioinformatics bridges the gap between biological discoveries and clinical applications, enabling early disease identification, therapy response confirmation, and prognosis prediction. It facilitates the integration and analysis of vast amounts of clinical data, hence advancing clinical research and enhancing therapeutic approaches.Main bodyThis review explores the role of translational bioinformatics in understanding and treating cardiovascular disease, specifically Myocardial Ischemia. It covers the discovery of novel biomarkers (miRNA, lncRNA, and tsRNA), analysis of genes and proteins, and integrated bioinformatics to identify differentially expressed genes. The study highlights the impact of personalized medicine, drug discovery, and repurposing through bioinformatics. Additionally, it examines the application of systems biology and network analysis to understand biological networks, and the use of clinical decision support systems to enhance patient care. This integrative approach demonstrates the potential of bioinformatics to improve cardiovascular health outcomes.ConclusionsCombining clinical and omics data using translational bioinformatics is critical for refining treatment regimens and speeding up medication repurposing. This comprehensive study emphasizes the necessity of combining interdisciplinary data to enhance patient outcomes in myocardial ischemia, minimize the global burden of cardiovascular-related deaths, and improve cardiovascular disease management.Graphical abstract
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
